On February 1, 2023 Onconova Therapeutics, Inc. (NASDAQ: ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, reported that the Company will be participating in the 2023 Guggenheim Oncology Conference taking place February 8-9, 2023 in New York City (Press release, Onconova Therapeutics, FEB 1, 2023, View Source [SID1234626722]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Steven Fruchtman, M.D., President & CEO of Onconova, will participate in a fireside chat on February 8, 2023, at 10:45 a.m. ET. A webcast of the fireside chat will be available here. Following the presentation, a replay will be archived on the "Corporate Events and Presentations" section of the Onconova website.

The Company will also be participating in 1×1 investor meetings at the conference on February 8 and 9, 2023. Meetings can be requested via Guggenheim.

On February 1, 2023 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, reported that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two scientific conferences this February, the Immuno-Oncology 360o Summit, taking place February 7-10 in New York, NY, and the Federation of American Societies for Experimental Biology (FASEB) Catalyst Conference, taking place virtually February 8-9, 2023 (Press release, Cue Biopharma, FEB 1, 2023, View Source [SID1234626721]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Suri will present an overview of Cue Biopharma’s Immuno-STAT (Selective Targeting and Alteration of T cells) platform and interleukin 2 (IL-2)-based CUE-100 series of biologics designed to enable selective targeting of IL-2 to tumor-specific T cells.

Presentation Details

Immuno-Oncology 360o
Presentation title: Development, Validation and Application of TCR-selective Engagers for In Vivo Modulation and Persistence of Cell Therapy Products in IO
Presenter: Anish Suri, Ph.D., president and chief scientific officer, Cue Biopharma
Session: Track A: Novel Engineered Cell Therapies and Concepts
Date and time: February 7, 2023, 4:25 – 4:40 p.m. ET

FASEB Catalyst Conference
Presentation title: Immuno-STATs: TCR-selective Engagers of Tumor-specific T Cells
Presenter: Anish Suri, Ph.D., president and chief scientific officer, Cue Biopharma
Date and time: February 9, 2023, 2:00 – 2:30 p.m. ET

On February 1, 2023 Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), reported that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences (Press release, Merus, FEB 1, 2023, View Source [SID1234626720]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Healthcare Talks/Oncology Conference: Wednesday, February 8 at 11:20-11:45 a.m. ET
SVB Securities Global Biopharma Conference: Tuesday, February 14 at 3:40-4:10 p.m. ET
Citi’s 2023 Oncology Leadership Summit: Thursday, February 23 at 10:00-11:00 a.m. ET
The webcasts of the presentations will be contemporaneously available on the Investors page of the Company’s website. Archived presentations will also be available there for a limited time after the event.

On February 1, 2023 Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that the Company granted an aggregate of 113,250 restricted stock units (RSUs) to ten newly-hired employees (Press release, Karyopharm, FEB 1, 2023, View Source [SID1234626719]). These RSU awards were granted as of January 31, 2023 pursuant to the Company’s 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each RSU award will vest over three years, with 33 1/3% percent of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the applicable employee’s employment commencement date. The vesting of each RSU award is subject to the employee’s continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee’s employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the applicable RSU agreement).

On February 1, 2023 Veracyte, Inc. (Nasdaq: VCYT) reported that six abstracts highlighting new data focused on the company’s Decipher urologic cancer testing offerings will be presented at the 2023 ASCO (Free ASCO Whitepaper) Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif. and online, February 16-18, 2023 (Press release, Veracyte, FEB 1, 2023, View Source [SID1234626718]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data being presented include new insights derived from Veracyte’s Decipher Genomics Resource for Intelligent Discovery (GRID) database, which suggest potential opportunities to further personalize treatment for men with prostate cancer. Additionally, researchers will present new Decipher Prostate Genomic Classifier clinical utility data from the prospective, phase 3, randomized clinical trial, G-MINOR (Genomics in Michigan ImpactiNg Observation or Radiation).

"Veracyte is committed to helping empower physicians with the insights they need to guide more informed, individualized treatment for patients with urologic cancers," said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. "The data being presented at this year’s ASCO (Free ASCO Whitepaper) GU Cancers Symposium advance our understanding of how our Decipher genomic tests and Decipher GRID database may help physicians further stratify risk and guide treatment decisions for their patients with prostate or bladder cancer."

Veracyte also expects additional data regarding the Decipher Prostate test to be highlighted in the following general session presentation:

Title:

Treatment Combinations for Patients Starting Androgen-Deprivation Therapy: Building on Recent Victories

Presenter:

Gerhardt Attard, M.D., Ph.D., University College London Cancer Institute

Date/Time:

Thursday, February 16, 10:00 a.m. – 11:30 a.m. PST

Location:

Level 3, Ballroom

Below are details of the abstracts that will be presented as posters at the 2023 ASCO (Free ASCO Whitepaper) GU Cancers Symposium in the Moscone Center in Moscone West, Level 1.

Title:

Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.

Presenter:

Adam Benjamin Weiner, M.D., UCLA

Date/Time:

February 16, 2023; 11:30 a.m. PST

Abstract #:

241

Poster #:

J6

Title:

Determining the impact of genomic classifier testing on patient-reported quality of life after prostatectomy: Results from the G-MINOR randomized trial.

Presenter:

Udit Singhal, M.D., University of Michigan

Date/Time:

February 16, 2023; 11:30 a.m. PST

Abstract #:

345

Poster #:

M3

Title:

Comparative transcriptomic analysis of DNA-damage response and androgen receptor pathway activity between biopsy and radical prostatectomy specimens before and after pre-operative real-time MRI-guided stereotactic body radiotherapy.

Presenter:

Himanshu Nagar, M.D., Weill Cornell Medicine

Date/Time:

February 16, 2023; 11:30 a.m. PST

Abstract #:

375

Poster #:

N13

Title:

Effect of neoadjuvant stereotactic body radiation therapy (SBRT) on the immune microenvironment of high-risk localized prostate cancer in paired transcriptomic analysis of pretreatment biopsy and irradiated prostatectomy specimens.

Presenter:

Ariel E. Marciscano, M.D., Weill Cornell Medical College

Date/Time:

February 16, 2023; 11:30 a.m. PST

Abstract #:

371

Poster #:

N9

Title:

Distinct gene expression patterns identify patients who relapse after neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study.

Presenter:

Moritz Reike, M.D., University of British Columbia

Date/Time:

February 17, 2023; 12:30 p.m. PST

Abstract #:

549

Poster #:

M12

Title:

Genomic analysis from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with MIBC undergoing cystectomy.

Presenter:

Shilpa Gupta, M.D., Cleveland Clinic Taussig Cancer Center

Date/Time:

February 17, 2023; 12:30 p.m. PST

Abstract #:

559

Poster #:

N2